Table 4.
Univariate analysis for the effects of receptor for advanced glycation end products (RAGE) genetic polymorphism and various clinicopatholgical parameters on the recurrence-free survival and overall survival of the patients with uterine cervical cancer
| Recurrence-free survival | Overall survival | |||
|---|---|---|---|---|
| Variable | p value | HR & 95% CIb | p value | HR & 95% CIb |
| RAGE genetic polymorphism | ||||
| rs1800624 TA/AA vs TTa | 0.156 | 0.35 (0.08-1.49) | 0.204 | 0.39 (0.09-1.67) |
| Clinicopathological characteristics | ||||
| Stage | ||||
| ≥ stage II vs stage Ia | 0.002 | 4.05 (1.67-9.83) | 0.002 | 4.31 (1.70-10.91) |
| Cell grading | ||||
| moderate & poor (grades 2/3) vs well (grade 1)a | 0.084 | 3.61 (0.84-15.48) | 0.046 | 7.74 (1.04-57.78) |
| Stromal invasion depth | ||||
| >10 mm vs ≤10 mma | 0.002 | 4.01 (1.65-9.70) | 0.003 | 4.15 (1.62-10.61) |
| Tumor diameter | ||||
| >4 cm vs ≤ 4cma | 0.013 | 2.87 (1.25-6.58) | 0.007 | 3.26 (1.39-7.62) |
| Parametrium | ||||
| invasion vs no invasiona | 0.016 | 2.71 (1.21-6.07) | 0.001 | 3.76 (1.66-8.49) |
| Vagina | ||||
| invasion vs no invasiona | 0.022 | 2.59 (1.15-5.85) | 0.394 | 1.47 (0.61-3.59) |
| Pelvic lymph node | ||||
| metastasis vs no metastasisa | 0.002 | 3.67 (1.64-8.22) | 0.001 | 4.06 (1.80-9.16) |
Statistical analyses: Kaplan-Meier curve model
aAs a comparison reference
bHR, hazard ratio and 95% CI, 95% confidence interval for RAGE genetic variant and clinicopathological variables, compared to their respective controls.